by Internet Medical Society
The FDA approved the drug Etanercept in 2012 to treat patients with moderately to severely active rheumatoid arthritis (RA), moderately to severely active polyarticular juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), active ankylosing spondylitis (AS) and chronic moderate to severe plaque psoriasis (PsO). Etanercept is the active ingredient composed of inactive ingredients L-arginine hydrochloride, sodium chloride, and sucrose in the vials. The single-dose vials of Etanercept come in 25 mg and 50 mg to administer subcutaneously. Etanercept 25 mg and 50 mg vials are readily available from licensed generic medicine suppliers.